A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. (NCT07021898)
A Phase 1 First-in-Human Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-4001 Monotherapy and in Combination in Patients With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.
Who can join: Review the eligibility criteria below.
Location: Sarah Cannon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Sarah Cannon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology — Irving, Texas
- NEXT Oncology — San Antonio, Texas
- Fred Hutchinson Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (858) 465-6511
Email: clinicaltrials@erasca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Solid Tumors
- Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) — Chicago, Illinois
- SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors — Newport Beach, California
- A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors — Santa Rosa, California
- The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. — Rochester, Minnesota
- SLV-324 Treatment of Metastatic Solid Tumors — Newport Beach, California
Explore by condition: All Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.